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Herein, we report the synthesis and structural characteristics of three tetrazole-containing 
compounds, 1-benzyl-1H-tetrazole (bntz), 1-benzyl-1H-tetrazol-5-amine (bntza) and 1-(4-
methoxybenzyl)-1H-tetrazol-5-amine (mbntza) and the corresponding silver(I) complexes of the 
general formula [Ag(NO3-O)(L-N4)2]n, L = bntz (1), bntza (2) and mbntza (3). Silver(I) 
complexes 1 – 3 and 1-benzyl-1H-tetrazoles have been studied in detail by NMR, IR and UV-Vis 
spectroscopic methods and the structures of 1 and 2 have been determined by single-crystal X-
ray diffraction analysis. The results of these analyses revealed a monodentate coordination of the 
ligands to Ag(I) ion via the N4 tetrazole nitrogen. The antimicrobial potential of silver(I) 
complexes 1 – 3 was evaluated against the broad panel of Gram-positive and Gram-negative 
bacteria and fungi, displaying their remarkable inhibiting activity with MIC (minimal inhibitory 
concentration) values in the range 2 – 8 and 0.16 – 1.25 μg/mL (3.8 – 16.3 and 0.31 – 2.15 μM), 
respectively. On the other hand, 1-benzyl-1H-tetrazoles used for the synthesis of the silver(I) 
complexes were not active against the investigated strains, suggesting that the activity of the 
complexes originates from the Ag(I) ion exclusively. Moreover, silver(I) complexes 1 – 3 have 
good therapeutic potential, which can be deduced from their moderate cytotoxicity on the human 
fibroblast cell line MRC5, with IC50 values falling in the range 30 – 60 μg/mL (57.7 – 103.4 
μM).  
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Silver(I) complexes exhibit a wide range of applications in the medicinal and analytical 
chemistry, catalysis and the polymer design [1,2]. The use of silver(I) complexes in medicine is 
mainly related to their well known antibacterial and antifungal properties which are attributed to 
the presence of Ag(I) ion [3-6]. This metal ion is highly toxic to microorganisms, well tolerated 
by mammalians and does not present a serious toxic risk to human body [7,8]. Nevertheless, 
silver poisoning can occur among people chronically exposed to this metal [5]. Thus, argyria, the 
permanent discoloration of the skin, has been observed in persons that have ingested both 
metallic silver and silver(I) compounds in small doses during a long time period [5]. Although 
most scientists believe that argyria is the most serious health effect caused by the silver, there are 
also a few reports claiming that silver can cause brain damage, seizure or a persistent vegetative 
state [5]. 
In comparison to the simple silver(I) salts, the complexes of this metal ion represent an 
alternative formulation of silver with tunable antimicrobial properties. Many silver(I) complexes 
have shown superior antimicrobial activity in comparison with the silver(I) salts [1,9], as well as 
lower in vitro cytotoxicity on the healthy human lung fibroblast cell line MRC5 and in vivo 
embryotoxicity [10]. One of the key factors determining the antimicrobial potential of silver(I) 
complexes is the type of donor atom coordinated to Ag(I) ion and, consequently, the rate of the 
ligand replacement rather than the complexes’ solubility, charge and degree of polymerization 
[11]. For instance, silver(I) complexes with nitrogen donors have shown an effective and wide-
spectrum antimicrobial activity [11-13]. The effectiveness of this type of silver(I) complexes was 




interaction with different biomolecules, such as thiol-containing proteins and nucleic acids, the 
process that is supposed to be a prerequisite for their antimicrobial action [6,11-13].  
Aromatic nitrogen-containing heterocyclic compounds (N-heterocycles) are one of 
the most important class of the nitrogen donor ligands utilized in the synthesis of 
biologically active silver(I) complexes [6]. These compounds represent structural 
moieties of many natural products and biologically important molecules, as well as 
pharmacologically used agents [14]. So far, different N-heterocycles such as imidazole 
and its substituted derivatives [7,15-18], tetrazole [19], pyridine and its derivatives [20-
24], quinolines [25], diazines and benzodiazines [9,10,26], bipyridines [27], terpyridines 
[28] and phenantrolines [29-36] have been used for the synthesis of mono- and 
polynuclear silver(I) complexes, which have shown a remarkable activity against a broad 
panel of bacterial and fungal strains which can lead to many infections.  
Even though tetrazoles, five-membered aromatic heterocycles which contain four 
nitrogen atoms within one ring, are not a part of any natural product, they have attracted 
considerable attention as structural components of energetic materials [37], bioactive compounds 
[38], nanomaterials [39] and as ligands for complexation to different metal ions [40-42]. Besides 
the unsubstituted tetrazole, there is a growing interest in the investigation of compounds 
containing N-linked substituents attached to the ring carbon of tetrazole, especially for 5-amino-
1H-tetrazole and its derivatives [40]. 5-Amino-1H-tetrazole motif is interesting, because it is 
nitrogen-rich compound which possesses five potential binding sites (one amino and four 
tetrazole nitrogen atoms) [43].  
 Herein, we have synthesized 1-benzyl-1H-tetrazole (bntz), 1-benzyl-1H-tetrazol-5-amine 




tetrazole motif [44] and used them as ligands for the synthesis of silver(I) complexes of the 
general formula [Ag(NO3-O)(L-N4)2]n, L = bntz (1), bntza (2) and mbntza (3) (Scheme 1). The 
1-benzyl-1H-tetrazoles and the corresponding silver(I) complexes were evaluated for in vitro 
antimicrobial and antiproliferative activities against the normal human lung fibroblast cell line to 
properly address their therapeutic potential. 
 
2. Experimental  
2.1. Materials and methods 
Unless stated otherwise, all solvents and reagents were obtained from commercial 
sources and used without further purification. Elemental microanalyses of the synthesized 1-
benzyl-1H-tetrazoles and silver(I) complexes for carbon, hydrogen and nitrogen were performed 
by the Microanalytical Laboratory, Faculty of Chemistry, University of Belgrade. The IR spectra 
were recorded as KBr pellets on a Perkin Elmer Spectrum 100 spectrometer over the 
wavenumber range of 4000 – 450 cm-1. The NMR spectra of the 1-benzyl-1H-tetrazoles and 
silver(I) complexes were recorded at 25 C on a Bruker Avance III Ultrashield (1H  at 500 MHz, 
13C at 125 MHz) and Bruker Avance III 400 MHz spectrometer (1H  at 400 MHz, 13C at 101 
MHz), respectively. In order to investigate the solution stability of silver(I) complexes, the 1H 
NMR spectra were recorded immediately after their dissolution in DMSO-d6, as well as after 48 
h standing in the dark at room temperature. The UV-Vis spectra were recorded on a Shimadzu 
spectrophotometer in DMSO/H2O (1 : 9, v/v). Compounds bntza and mbntza were analyzed by 
high resolution tandem mass spectrometry using LTQ Orbitrap XL (Thermo Fisher Scientific 
Inc., USA) mass spectrometer. The sample was dissolved in CH3CN and it was injected directly. 




parameters were: spray voltage 4.7 kV, vaporizer temperature 60 °C, sheath and auxiliary gas 
flow 24 and 10 (arbitrary units), respectively, capillary voltage 49 V, capillary temperature 275 
°C, tube lens voltage 80 V, resolution (at m/z 400): 30000. 
 
2.2. Synthesis of 1-benzyl-1H-tetrazoles 
The tetrazole-containing compounds, 1-benzyl-1H-tetrazole (bntz), 1-benzyl-1H-tetrazol-
5-amine (bntza) and 1-(4-methoxybenzyl)-1H-tetrazol-5-amine (mbntza), were synthesized by 
previously described methods [45,46]. These compounds were pure based on elemental 
microanalysis and NMR spectroscopy.  
 
2.2.1. 1-Benzyl-1H-tetrazole (bntz)  
1-Benzyl-1H-tetrazole (bntz) was synthesized according to the procedure described by 
Satoh and Marcopulos as a yellow crystalline solid (see Supplementary data) [45]. Yield: 40% 
(598.0 mg). Mp 52 – 55 °C. IR (KBr, ν, cm-1): 3113, 3065 (ν(Car–H)), ~3000 (ν(C–H)), 1670 
(ν(Car=N)), 1495 (ν(N–Car=N)), 1465 (δ(CH2)), 1386 (ν(N=N)), 1243 (ν(C–N)), 1162 (ν(N–N)), 
710 (γ(Car–H)). 1H NMR (500 Hz, CDCl3): δ 5.60 (s, 2H, C6H), 7.29 – 7.32 (m, 2H, C8H and 
C12H), 7.38 – 7.42 (m, 3H, C9H – C11H), 8.57 ppm (s, 1H, C5H). 13C{1H} NMR (125 Hz, 
CDCl3): δ 52.09 (C6), 128.23 (C8 and C12), 129.29 (C10), 129.33 (C9 and C11), 132.78 (C7), 
142.38 ppm (C5). UV-Vis (DMSO/H2O, λmax, nm): 257.0 (ε = 3.6
.102 M-1cm-1).  
 
2.2.2. 1-Benzyl-1H-tetrazol-5-amine (bntza)  
The amino-containing bntza compound was synthesized according to the previously 




Mp 184 – 186 °C. IR (KBr, ν, cm-1): 3338 (νas(NH2)), 3153 (νs(NH2)), 3064 (ν(Car–H)), ~3000 
(ν(C–H)), 1642 (ν(Car=N)), 1485 (ν(N–Car=N)), 1430 (δ(CH2)), 1336 (ν(N=N)), 1269 (ν(C–N)), 
1125 (ν(N–N)), 723 (γ(Car–H)). 1H NMR (500 Hz, DMSO-d6): δ 5.35 (s, 2H, C6H), 6.82 (s, 2H, 
NH2), 7.20 – 7.24 (m, 2H, C8H and C12H), 7.28 – 7.32 (m, 1H, C10H), 7.33 – 7.38 ppm (m, 2H, 
C9H and C11H). 13C{1H} NMR (125 Hz, DMSO-d6): δ 47.53 (C6), 127.52 (C8 and C12), 
127.93 (C10), 128.70 (C9 and C11), 135.41 (C7), 155.52 ppm (C5). UV-Vis (DMSO/H2O, λmax, 
nm): 238.0 (ε = 2.4.103 M-1cm-1). HRMS (HESI/Orbitrap) m/z [M + H]+ calc for C8H10N5: 
176.09362; found 176.09299. 
 
2.2.3. 1-(4-Methoxybenzyl)-1H-tetrazol-5-amine (mbntza) 
Following the procedure described for bntza [46], compound mbntza was obtained from 
4-(methoxyphenyl)methanamine as a colorless crystalline solid. Yield: 62% (185.0 mg). Mp 
183 – 185 °C. IR (KBr, ν, cm-1): 3332 (νas(NH2)), 3162 (νs(NH2)), 3025, 2961 (ν(Car–H)), 2840, 
2742 (ν(C–H)), 1660 (ν(Car=N)), 1513 (ν(N–Car=N)), 1458 (δ(CH3)), 1436 (δ(CH2)), 1307 
(ν(N=N)), 1281 (ν(C–N)), 1253 (ν(C–O)), 1182 (ν(N–N)), 792, 677 (γ(Car–H)). 1H NMR (500 
Hz, DMSO-d6): δ 3.72 (s, 3H, OCH3), 5.26 (s, 2H, C6H), 6.79 (s, 2H, NH2), 6.91 (d, J = 9.0 Hz, 
2H, C9H and C11H), 7.21 ppm (d, J = 9.0 Hz, 2H, C8H and C12H). 13C{1H} NMR (125 Hz, 
DMSO-d6): δ 47.11 (C6), 55.13 (OCH3), 114.08 (C9 and C11), 127.31 (C7), 129.21 (C8 and 
C12), 155.00 (C5), 159.01 ppm (C10). UV-Vis (DMSO/H2O, λmax, nm): 238.0 (ε = 3.5
.103  
M-1cm-1), 273.0 (ε = 1.4.103 M-1cm-1). HRMS (HESI/Orbitrap) m/z [M + Na]+ calc for 






2.3. Synthesis of silver(I) complexes 1 – 3  
Silver(I) complexes with 1-benzyl-1H-tetrazoles, [Ag(NO3-O)(bntz-N4)2]n (1), [Ag(NO3-
O)(bntza-N4)2]n (2) and [Ag(NO3-O)(mbntza-N4)2]n (3), were synthesized in accordance to the 
previously described method for the preparation of the silver(I) complexes with 
diazanaphthalenes [10]. The purity of the complexes was confirmed by elemental microanalysis 
and NMR spectroscopy.  
The solution of 1.0 mmol of the corresponding 1-benzyl-1H-tetrazole (160.2 mg of bntz 
for 1, 175.2 mg of bntza for 2 and 205.2 mg of mbntza for 3) in 5.0 mL of ethanol was added 
slowly under stirring to the solution containing an equimolar amount of AgNO3 (169.9 mg) in 
10.0 mL of ethanol. The reaction mixture was stirred for 3 – 4 h on a magnetic stirrer, in a sealed 
round-bottom flask, protected from light at room temperature. Complexes 1 and 3 were obtained 
from the mother ethanol solution after its cooling in the refrigerator for several days. The crystals 
of complex 2 were obtained after the crude product, resulting from the reaction of AgNO3 and 
bntza, was dissolved in 10 mL of acetonitrile. Yield (calculated on the basis of the N-
heterocyclic ligand): 152.0 mg (62%) for 1, 189.9 mg (73%) for 2 and 191.5 mg (66%) for 3. 
Anal. calcd. for 1 (C16H16AgN9O3; MW = 490.25): C, 39.20; H, 3.29; N, 25.71. Found: 
C, 38.87; H, 3.22; N, 26.04%. IR (KBr, ν, cm-1): 3113 (ν(Car–H)), ~3000 (ν(C–H)), 1654 
(ν(Car=N)), 1494 (ν(N–Car=N)), 1384, 1354 (νas(NO3)), 1244 (ν(C–N)), 1164 (ν(N–N)), 711 
(γ(Car–H)). 1H NMR (400 Hz, DMSO-d6): δ 5.72 (s, 2H, C6H), 7.30 – 7.44 (m, 5H, C8H – 
C12H), 9.53 ppm (s, 1H, C5H). 13C{1H} NMR (101 Hz, DMSO-d6): δ 51.26 (C6), 128.62 (C8 
and C12), 128.94 (C10), 129.37 (C9 and C11), 135.31 (C7), 144.51 ppm (C5). UV-Vis 
(DMSO/H2O, λmax, nm): 257.0 (ε = 5.3




Anal. calcd. for 2 (C16H18AgN11O3; MW = 520.28): C, 36.94; H, 3.49; N, 29.62. Found: 
C, 36.65; H, 3.62; N, 29.88%. IR (KBr, ν, cm-1): 3322 (νas(NH2)), 3203 (νs(NH2)), ~3000 (ν(Car–
H) and ν(C–H)), 1647 (ν(Car=N)), 1483 (ν(N–Car=N)), 1440 (δ(CH2)), 1384, 1364 (νas(NO3)), 
1334 (ν(N=N)), 1204 (ν(C–N)), 1144 (ν(N–N)), 708 (γ(Car–H)). 1H NMR (400 Hz, DMSO-d6): 
δ 5.38 (s, 2H, C6H), 6.90 (s, 2H, NH2), 7.24 (d, J = 6.9 Hz, 2H, C8H and C12H), 7.33 (d, J = 7.1 
Hz, 1H, C10H), 7.38 ppm (t, J = 7.1 Hz, 2H, C9H and C11H). 13C{1H} NMR (101 Hz, DMSO-
d6): δ 48.12 (C6), 128.02 (C8 and C12), 128.44 (C10), 129.19 (C9 and C11), 135.79 (C7), 
155.96 ppm (C5). UV-Vis (DMSO/H2O, λmax, nm): 239.0 (ε = 2.1
.103 M-1cm-1).  
Anal. calcd. for 3 (C18H22AgN11O5; MW = 580.31): C, 37.25; H, 3.82; N, 26.55. Found: 
C, 36.60; H, 3.63; N, 26.19%. IR (KBr, ν, cm-1): 3337 (νas(NH2)), 3160 (νs(NH2)), ~3000 (ν(Car–
H) and ν(C–H)), 1656 (ν(Car=N)), 1514 (ν(N–Car=N)), 1478 (δ(CH3)), 1441 (δ(CH2)), 1384, 
1306 (νas(NO3)), 1253 (ν(C–O)), 1181 (ν(N–N)), 792 (γ(Car–H)). 1H NMR (400 Hz, DMSO-d6): 
δ 3.73 (s, 3H, OCH3), 5.28 (s, 2H, C6H), 6.86 (s, 2H, NH2), 6.92 (d, J = 8.6 Hz, 2H, C9H and 
C11H), 7.22 ppm (d, J = 8.6 Hz, 2H, C8H and C12H). 13C{1H} NMR (101 Hz, DMSO-d6): δ 
47.64 (C6), 55.60 (OCH3), 114.56 (C9 and C11), 127.70 (C7), 129.70 (C8 and C12), 155.73 
(C5), 159.49 ppm (C10). UV-Vis (DMSO/H2O, λmax, nm): 238.0 (ε = 3.4
.103 M-1cm-1), 273.0 (ε 
= 1.4.103 M-1cm-1).  
 
2.4. Crystallographic data collection and refinement of the structures 
Crystal data and details of the structure determinations are compiled in Table 1. Full 
shells of intensity data were collected at low temperature with an Agilent Technologies 
Supernova-E CCD diffractometer (Mo- or Cu-K radiation, microfocus X-ray tube, multilayer 




integrated by profile fitting [47,48]. Data were corrected for air and detector absorption, Lorentz 
and polarization effects and scaled essentially by application of appropriate spherical harmonic 
functions [48-50]. Absorption by the crystal was treated with a semiempirical multiscan method 
(as part of the scaling process) and augmented by a spherical correction [49,50] or numerically 
(Gaussian grid) [48,51]. An illumination correction was performed as part of the numerical 
absorption correction [49]. The structures were solved by “modern” direct methods with dual-
space recycling (VLD procedure [52], complex 1) or by intrinsic phasing [53] and refined by 
full-matrix least squares methods based on F2 against all unique reflections [54]. All non-
hydrogen atoms were given anisotropic displacement parameters. Hydrogen atoms were 
generally input at calculated positions and refined with a riding model. The positions of the 
hydrogen atoms of the amino groups in 2 were taken from difference Fourier syntheses and 
refined. MERCURY computer graphics program was used to prepare drawings [55].  
 
Table 1  
Details of the crystal structure determinations of the silver(I) complexes 1 and 2. 
 1 2 
Empirical formula C16H16AgN9O3 C16H18AgN11O3 
Formula weight 490.25 520.28 
Crystal system, space group orthorhombic, Pna21 triclinic, Pī 
a (Å) 15.2438(4) 11.8862(3) 
b (Å) 22.2842(5) 12.3342(2) 
c (Å) 5.49642(15) 15.4198(3) 
 (°)  106.1444(16) 
  (°)  112.1390(19) 




V (Å3) 1867.11(8) 1956.92(7) 
F000 984 1048 
 4 4 
X-radiation, /Å  Cu-Kα 1.54184  Mo-Kα 0.71073 
data collect. temperat. / K 120(1) 120(1) 
Calculated density (Mg m-3) 1.744 1.766 
Absorption coefficient  (mm-1) 9.023 1.077 
Crystal size (mm3) 0.087 × 0.050 × 0.023 0.099 × 0.089 × 0.057 
 range  (°) 3.5 to 71.0 2.3 to 32.5 
index ranges h, k, l -18 ... 18, -27 ... 27, -6 ... 
6 
-17 ... 17, -18 ... 18, -23 ... 
23 
No. of collected, independent and 
observed [I > 2(I)] reflections 
59328, 3589, 3313 48945, 13254, 8558 
Rint 0.0471 0.0392 
Transmission factors: max, min 0.852, 0.574 1.0000, 0.9795 
Data / restraints / parameters 3589 / 1 / 262 13254 / 0 / 583 
Goodness-on-fit on F2 1.052 1.016 
Final R indices 
 [Fo > 4(Fo)] R(F), wR(F
2) 
0.0444, 0.1129 0.0338, 0.0676 
Final R indices 
 (all data) R(F), wR(F2) 
0.0483, 0.1167 0.0642, 0.0787 
Absolute structure parameter 0.008(4)  
Difference density: rms, max, min (e Å-3) 0.112, 0.460, -1.490 0.092, 0.557, -0.425 
CCDC deposition number 1851085 1851086 
 
 
2.5. Quantum-mechanical calculations 
All DFT calculations were carried out at the B3LYP level of theory using 6-31G**+ 




Schrödinger, LLC, New York, NY, 2018.). The B3LYP method is known to give good 
descriptions of transition metal complexes [56]. All structures were prepared in Schrödinger 
Suite and optimized in Jaguar using same aforementioned parameters prior to calculation. 
 
2.6. Antimicrobial studies 
MIC concentrations of 1 – 3 and 1-benzyl-1H-tetrazole ligands were determined 
according to the standard broth microdilution assays, recommended by the National Committee 
for Clinical Laboratory Standards (M07-A8) for bacteria and Standards of European Committee 
on Antimicrobial Susceptibility Testing (v 7.3.1: Method for the determination of broth dilution 
minimum inhibitory concentrations of antifungal agents for yeasts) for Candida spp. The tested 
compounds were dissolved in DMSO at 50 mg/mL. The highest concentration used was 500 
µg/mL. Bacterial test organisms included: Staphylococcus aureus ATCC 25923, Listeria 
monocytogenes NCTC 11994, Micrococcus luteus ATCC 379, Pseudomonas aeruginosa PAO1 
NCTC 10322, and Candida strains: C. albicans ATCC 10231, C. glabrata ATCC 2001, C. 
krusei ATCC 6258, C. parapsilosis ATCC 22019. The inoculums were 105 colony forming units, 
cfu/mL, for bacteria and 104 cfu/mL for Candida spp. The MIC value was recorded as the lowest 
concentration that inhibited the growth after 24 h at 37 °C.  
 
2.7. In vitro cytotoxicity assay 
Cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay [57]. The assay was carried out using human lung fibroblasts (MRC5) 
after 48 h of cell incubation in the media, containing compounds at concentrations ranging from 




with 100 μg/mL streptomycin, 100 U/mL penicillin and 10% (v/v) fetal bovine serum (FBS) (all 
from Sigma, Munich, Germany) as a monolayer (1 x 104 cells per well) and grown in humidified 
atmosphere of 95% air and 5% CO2 at 37 °C. The extent of MTT reduction was measured 
spectrophotometrically at 540 nm using a Tecan Infinite 200 Pro multiplate reader (Tecan Group 
Ltd., Männedorf, Switzerland), and the cell survival was expressed as percentage of the control 
(untreated cells).  The percentage viability values were plotted against the log of concentration 
and a sigmoidal dose response curve was calculated by non-linear regression analysis, using the 
Graphpad Prism software, version 5.0 for Windows (Graphpad Software, CA, USA).  
Cytotoxicity is expressed as the concentration of the compound inhibiting growth by 50% (IC50). 
 
3. Results and discussion 
3.1. Synthesis and structural characterization of 1-benzyl-1H-tetrazoles and the silver(I) 
complexes 1 – 3 
Three tetrazole-containing compounds, 1-benzyl-1H-tetrazole (bntz), 1-benzyl-1H-
tetrazol-5-amine (bntza) and 1-(4-methoxybenzyl)-1H-tetrazol-5-amine (mbntza), were 
synthesized by the previously reported methods (Scheme S1) [45,46]. They further reacted with 
AgNO3 in 1 : 1 mole ratio in ethanol at room temperature to yield [Ag(NO3-O)(bntz-N4)2]n (1), 
[Ag(NO3-O)(bntza-N4)2]n (2) and [Ag(NO3-O)(mbntza-N4)2]n (3) complexes (Scheme 1). In 
complexes 1 – 3, the corresponding tetrazole ligand is monodentatedly coordinated to Ag(I) ion 








Scheme 1. Schematic presentation of the reactions for the synthesis of the silver(I) complexes 1 
– 3. Numbering scheme of nitrogen and carbon atoms in 1-benzyl-1H-tetrazoles does not match 
the one applied in the X-ray study of silver(I) complexes 1 and 2. 
 
3.1.1. Spectroscopic characterization 
The NMR (1H and 13C), IR and UV-Vis spectroscopic data for the 1-benzyl-1H-tetrazoles 
and the corresponding silver(I) complexes 1 – 3 are given in the Experimental section. The 1H 
and 13C NMR spectra for 1 – 3 are similar to those of the uncoordinated 1-benzyl-1H-tetrazoles 
and, in most cases, only small shifts of the proton and carbon signals for complexes 1 – 3 with 
respect to those for the ligands are observed, what seems to be a spectroscopic feature of silver(I) 
complexes in solution [16]. All proton signals of 1 – 3 are shifted downfield in respect to those 
of the corresponding 1-benzyl-1H-tetrazoles. The chemical shifts of the protons after ligand 
coordination to Ag(I) are strongly dependent on the proton position relative to the metal ion. Of 




binding center, i.e. C5H proton, in the spectrum of 1. Thus, C5H in the spectrum of 
uncoordinated bntz gives a singlet at δ 8.57 ppm, and it was shifted downfield at 9.53 ppm (Δδ = 
0.96 ppm) after its coordination to the Ag(I) ion. For the complexes 1 – 3, 1H NMR spectra 
remained unmodified over 48 h, indicating their stability in solution during that time. More 
specifically, no decomposition of the complexes to the free ligands and no coordination of 
DMSO to Ag(I) were observed.  
From the 13C spectra of the complex 1, it can be concluded that bntz is coordinated to the 
Ag(I) ion through the N4 tetrazole nitrogen, considering the large shift (Δδ = 2.13 ppm) for the 
N4 adjacent carbon, C5, compared to the uncoordinated bntz. On the other hand, only a small 
shift of ~1 ppm is observed for the carbon atoms of bntza and mbntza after their coordination to 
Ag(I).  
The IR spectra of the complexes 1 – 3, in comparison to those of 1-benzyl-1H-tetrazoles, 
display certain differences which may give an insight in the type of bonds and their structures. A 
band attributed to the nitrate asymmetric stretching vibrations in the IR spectra of 1 – 3 is split 
into two bands with relatively small separation, being an indication of nitrate coordination in 
these complexes [58]. The splitting of the nitrate asymmetric stretching vibrations in the IR 
spectra of 1 – 3 is in accordance with that observed for the polynuclear [Ag(NO3)(qz)]n complex 
(qz is quinazoline) which contains nitrate as a bridging ligand between two Ag(I) ions [9]. The 
IR spectra of complexes 2 and 3 also show the expected bands at approximately 3300 and 3200 
cm-1, which are due to the asymmetric and symmetric stretching vibrations of the amino group, 
respectively [59]. 
The UV-Vis spectra of silver(I) complexes 1 – 3, recorded in DMSO/H2O, resemble 




corresponding absorbance peaks at ~ 257.0 and 239.0 nm, respectively, are caused by the 
characteristic π → π* transitions in the ligand [60,61]. The absorbance peak for 2 shows slight 
red shift compared to that for the free ligand (λ = 238.0 nm).  The UV-vis spectra of mbntza and 
the corresponding complex 3 have two maximum absorbance peaks at 238.0 and 273.0 nm, 
which can be assigned to π → π* transition of the phenyl ring and n → π* intraligand transition 
of its methoxy group, respectively [62].  
 
3.1.2. Description of the single crystal structures  
The molecular structures of complexes 1 and 2 with the crystallographic numbering 
scheme are depicted in Fig. 1. The relevant bond distances and angles with their estimated 
standard deviations are presented in Table 2.   
 Silver(I) complex 1 with 1-benzyl-1H-tetrazole is polynuclear. Each Ag(I) ion is 
surrounded by two bntz ligands, which are coordinated via the nitrogen adjacent to the tetrazole 
carbon (N1 and N5, Fig. 1) and by two nitrates. Two Ag(I) ions are connected by one nitrate, 
which behaves as bidentate bridging ligand (d(Ag–O) = 2.506(7) and 2.491(6) Å). The 
coordination geometry around Ag(I) in distorted tetrahedral, what emerges from the τ4 parameter 
of 0.70, τ4 = [360
o – (β + α)]/141o, where β and α are the largest angles involving the metal center 
(square-planar and tetrahedral geometries result in τ4 values of 0 and 1) [63]. The average Ag–
N(tetrazole) and Ag–O(nitrate) bond distances are 2.252 and 2.498 Å, respectively (Table 2) and 





















Fig. 1. Molecular structures of silver(I) complexes 1 and 2. Displacement ellipsoids are drawn at 
50% probability level and H atoms are represented by spheres of arbitrary size. 
 
Similar to 1, silver(I) complex 2 contains two monodentatedly coordinated 1-
benzyl-1H-tetrazol-5-amine via the nitrogen adjacent to the tetrazole carbon (N1/N51 and 
N6/N56, Fig. 1). The coordinated tetrazole nitrogens of the two bntza ligands are almost 
equidistant from the Ag(I) ion (Table 2) and are in agreement with the other silver(I) 




in bifurcated hydrogen bonding with the amino groups of both tetrazolamino ligands on 
the same silver(I) ion (Table 3). An additional comparatively weak interaction of two 
nitrate oxygens with the silver(I) ions leads to polymeric Ag-(NO3)-Ag-(NO3)- chains 
(Table 2). Interestingly, an ordered superstructure with a dinuclear [Ag(NO3)(bntza)2]2 
repetition unit is formed, with the only significant difference between the two very similar 
mononuclear subunits being the rotational conformations of the benzyl substituents. 
 
Table 2  
Selected bond distances (Å) and valence angles (o) in silver(I) complexes 1 and 2. 
1 2 
Ag—O1 2.506(7) Ag1—N1 2.1155(16) 
Ag—O2i 2.491(6) Ag1—N6 2.1100(17) 
Ag—N1 2.241(5) Ag51—N51 2.1202(17) 
Ag—N5 2.264(5) Ag51—N56 2.1145(17) 
O1—N9 1.259(11) Ag1-O81 2.6859(16) 
O2—N9 1.241(11) Ag1-O92 2.8882(15) 
O3—N9 1.255(7) Ag51-O82iii 2.8644(15) 
  Ag51-O91 2.6579(16) 
    
O1—Ag—O2i 83.80(15) N1—Ag1—N6 175.67(7) 
N1—Ag—O1 112.9(2) N2—N1—Ag1 121.14(3) 
N1—Ag—O2i 101.7(2) C1—N1—Ag1 131.99(14) 
N1—Ag—N5 148.56(18) N7—N6—Ag1 122.22(13) 
N5—Ag—O1 95.6(2) C9—N6—Ag1 130.58(14) 
N5—Ag—O2i 93.9(2) N51—Ag51—N56 174.66(7) 
N9—O1—Ag 100.0(5) N52—N51—Ag51 122.78(13) 
N9—O2—Agii 103.9(4) C51—N51—Ag51 130.32(14) 
N2—N1—Ag 123.4(4) N57—N56—Ag51 120.84(13) 
C1—N1—Ag 129.8(4) C59—N56—Ag51 132.34(14) 
N6—N5—Ag 122.7(4)   
C9—N5—Ag 130.4(5)   






Table 3  
Hydrogen bond parameters for silver(I) complex 2.  
D—H···A D—H (Å) H···A (Å) D···A (Å) D—H···A (º) 
N5—H5a···O92 0.88(2) 1.97(2) 2.839(2) 170(2) 
N10—H10B···O83i 0.82(3) 2.06(3) 2.866(3) 169(3) 
N55—H55A···O82ii 0.81(2) 2.04(3) 2.847(2) 171(2) 
N60—H60B···O93iii 0.80(3) 2.08(3) 2.862(3) 164(3) 
Symmetry codes: (i) −x+2, −y+1, −z+2; (ii) x, y+1, z; (iii) –x+2, −y+2, −z+2 
 
 
3.2.Computational studies  
In order to gain a better understanding of the coordination mode of the synthesized 1-
benzyl-1H-tetrazoles toward the Ag(I) ion, the structures of bntz and bntza were optimized and 
their molecular electrostatic potential (MEP) mapped on electron density surface generated at 
B3LYP/6-31G**+ level of theory was examined (Fig. 2a). The MEP is a useful property for 
analyzing and predicting the sites or regions of a molecule to which an approaching electrophile 
(metal ion) is initially attracted [67,68]. The regions of negative potential are colored in red, 
while the blue regions have positive potential. From Fig. 2a, one could see that in bntz and bntza 
molecules, the negative electrostatic region is localized on the N3 and N4 tetrazole nitrogens, 
indicating that both of these donors are almost equally accessible to metal ion. However, the 
results of calculations suggest that the electron density in the HOMO (Highest Occupied 
Molecular Orbital) is mainly distributed over the tetrazole ring, and some slight preference for 
the coordinating nitrogen atom N4 could be found (Fig. 2b). These theoretical findings are in line 
with the X-ray results for the complexes 1 and 2, all together supporting the selective formation 
of silver(I) complexes in which the corresponding tetrazole-containing ligand is coordinated via 


















Fig. 2. a) Electrostatic potential mapped on electron density surfaces for the bntz and bntza 
generated at DFT B3LYP/6-31G**+ level of theory (isoval 0.0025 a.u.). Color change from red 
most negative to blue most positive. b) HOMO orbitals of bntz and bntza. 
 
3.3. Antimicrobial and cytotoxic activity of the 1-benzyl-1H-tetrazoles and silver(I) complexes  
1 – 3 
Given the traditional antimicrobial effects exerted by silver-containing materials and 








corresponding ligands have been evaluated against the panel of bacteria and Candida strains 
(Table 4). While 1-benzyl-1H-tetrazoles used for the synthesis of the silver(I) complexes were 
not active against the investigated strains at concentrations higher than 500 µg/mL (data not 
shown), 1 – 3 showed growth inhibiting activity against all tested strains, suggesting that the 
activity of the complexes originates from the presence of Ag(I) ions. The MIC values of the 
silver(I) complexes were between 2 – 8 µg/mL (3.8 – 16.3 µM) against bacterial strains, while 
they were able to inhibit Candida, both albicans and non-albicans strains at 0.16 – 1.25 µg/mL 
(0.31 – 2.15 µM) MIC concentration values (Table 4). Three complexes exhibited comparable 
activity, with 2 being slightly more active across the microbial panel. From these data, no 
difference has been observed between Gram-positive and Gram-negative strains, while anti-
Candida activity of these complexes was more prominent, with C. parapsilosis being the most 
sensitive strain. More importantly, 1 – 3 were moderately cytotoxic against human lung 
fibroblast cell line, with the best selectivity index being 312 (for 1 and C. parapsilosis) giving 
reason for further evaluations of these complexes for therapeutic applications. These results are 
of special importance having in mind, that emerging non-albicans Candida species, such as C. 
parapsilosis, C. glabrata, C. tropicalis and C. krusei, are increasingly recognized as causative 
agents of infections ranging from superficial to life-threatening disseminated bloodstream and 
deep-tissue infections [69].  
Good antimicrobial activity of 1 – 3 was comparable or slightly better to that observed 
for silver(I) complexes with aromatic nitrogen-containing heterocycles such as pyridazine, 
pyrimidine, pyrazine, quinoxaline, phenazine, quinazoline and phthalazine [9,10,26]. Unlike these 
complexes, 1 – 3 showed higher activity against selection of Candida strains. Improved activity 




complexes with coordinated 4-(hydroxymethyl)pyridine, 2,6-di(hydroxymethyl)pyridine and 2-
(hydroxymethyl)benzimidazole (MIC = 10 – 20 μg/mL) [23]. Notably, 1 – 3 did not cause 
significant cytotoxic effect in vitro, which is usually observed with Ag(I) complexes [9]. 
 
Table 4 
Minimal inhibitory concentrations (MIC) against a panel of microorganisms and antiproliferative 
activity (IC50) of 1 – 3.  
Compound 1 2 3 
Organism µg/mL µM µg/mL µM µg/m
L 
µM 
Staphylococcus aureus 4 8.2 2 3.8 4 6.9 
Listeria monocytogenes 4 8.2 2 3.8 8 13.8 
Micrococcus luteus 8 16.3 2 3.8 4 6.9 
Pseudomonas aeruginosa PAO1 2 4.1 2 3.8 4 6.9 
Candida albicans 0.62 1.26 0.62 1.19 1.25 2.15 
Candida glabrata 0.62 1.26 0.62 1.19 1.25 2.15 
Candida krusei 0.62 1.26 0.31 0.60 0.62 1.07 
Candida parapsilosis 0.16 0.33 0.16 0.31 0.31 0.53 
MRC5 (human lung fibroblasts)a 50 102.0 30 57.7 60 103.4 
aIC50 is defined as the concentration inhibiting 50% of cell growth after 48 h treatment with the 
tested compounds. Results are from three independent experiments, each performed in triplicate. 
Standard deviations were within 1-3%. 
 
4. Conclusions 
We have demonstrated that the tetrazole-containing ligands, 1-benzyl-1H-tetrazole (bntz), 
1-benzyl-1H-tetrazol-5-amine (bntza) and 1-(4-methoxybenzyl)-1H-tetrazol-5-amine (mbntza), 
can selectively bind to the Ag(I) ion via the nitrogen atom N4 which is adjacent to the carbon 
atom of the tetrazole ring. All these ligands coordinate to the Ag(I) ion to form polynuclear 
species, in which nitrate acts as a bridging ligand between two Ag(I) ions. Of a series of the 




and bacterial strains is observed for the silver(I) complex [Ag(NO3-O)(bntza-N4)2]n, with 
tetrazole ligand containing the amino group and unsubstituted benzyl ring. At the same time, this 
complex is the most cytotoxic; nevertheless, its selectivity indices are, in some cases, higher than 
180. These findings serve as a basis for further design of tetrazole-containing compounds, which 
could be used as ligands for complexation of Ag(I) ion, what can be of importance for the 
development of novel silver-based antimicrobials.  
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Table and Figure Captions 
Table 1  
Details of the crystal structure determinations of the silver(I) complexes 1 and 2. 
Table 2  
Selected bond distances (Å) and valence angles (o) in silver(I) complexes 1 and 2. 
Table 3  
Hydrogen bond parameters for silver(I) complex 2.  
Table 4 
Minimal inhibitory concentrations (MIC) against a panel of microorganisms and antiproliferative 
activity (IC50) of 1 – 3.  
 
Scheme 1. Schematic presentation of the reactions for the synthesis of the silver(I) complexes 1 
– 3. Numbering scheme of nitrogen and carbon atoms in 1-benzyl-1H-tetrazoles does not match 
the one applied in the X-ray study of silver(I) complexes 1 and 2. 
Fig. 1. Molecular structures of silver(I) complexes 1 and 2. Displacement ellipsoids are drawn at 
50% probability level and H atoms are represented by spheres of arbitrary size. 
Fig. 2. a) Electrostatic potential mapped on electron density surfaces for the bntz and bntza 
generated at DFT B3LYP/6-31G**+ level of theory (isoval 0.0025 a.u.). Color change from red 





1-Benzyl-1H-tetrazoles were used as ligands for the synthesis of silver(I) complexes which have 
shown remarkable antimicrobial activity against the different fungal and bacterial strains and 
good therapeutic potential. 
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